Categories AlphaGraphs, Earnings, Retail

Lowe’s shares fall on earnings miss

Lowe’s (LOW) today reported lower-than-expected Q1 earnings, sending its shares down as much as 8% during the pre-market trading.  The Mooresville, North Carolina-based company reported almost 70% jump in earnings to $1.19 per share but it came below the analysts’ estimate of $1.22 per share.

The new revenue recognition accounting standard helped the home improvement retailer post a 3% rise in revenue to $17.4 billion during the quarter. This also failed to meet the consensus estimate of $17.44 billion. Comparable sales grew 0.6%, missing street estimate of 3.06% growth.

“We drove solid performance in indoor categories and continued to grow our sales to Pro customers.  However, prolonged unfavorable weather across geographies led to a delayed spring selling season, which impacted results in outdoor categories. Spring has now arrived and we are encouraged by strong sales in the month of May,” said Robert Niblock, CEO.

Lowe's first quarter 2018 earnings

The company, which recently tapped JCPenney (JCP) CEO Marvin Ellison as its new CEO, expects sales to increase approx 5% in fiscal 2018. Comparable sales are expected to increase approx 3.5% during this period. For the fiscal year ending Feb. 1, 2019, the company expects EPS of $5.40 to $5.50.

Analysts hope that the new CEO can help revive Lowe’s business and strengthen the company’s performance, like Home Depot.

As of May 4, 2018, Lowe’s operated 2,154 home improvement and hardware stores in the US, Canada, and Mexico, representing 215.1 million square feet of retail selling space.

A similar unfavorable weather condition had plagued rival Home Depot (HD) also. After the earnings results, share price of Home Depot fell over 1% due to weakness in comparable sales growth. During Q1, Home Depot reported EPS of $2.08 and revenue of $24.95 billion.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top